Acorda Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year Five
Acorda Therapeutics, Inc. had Finite-Lived Intangible Asset, Expected Amortization, Year Five of $2.58 million as of 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Intangible Assets › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive · last filed 2024-04-01
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $2.58M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $30.76M.
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $30.76M.
- 2020-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $30.76M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Five |
|---|---|
| 2023-12-31 | $2.58M 10-K · filed 2024-04-01 |
| 2022-12-31 | $30.76M 10-K · filed 2023-03-15 |
| 2021-12-31 | $30.76M 10-K · filed 2022-03-18 |
| 2020-12-31 | $30.76M 10-K · filed 2021-03-16 |
| 2019-12-31 | $30.76M 10-K · filed 2020-02-28 |
| 2018-12-31 | $30.39M 10-K · filed 2019-02-27 |
| 2016-12-31 | $9.58M 10-K · filed 2017-02-27 |
| 2016-09-30 | $9.60M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $9.60M 10-Q · filed 2016-08-04 |
| 2015-12-31 | $316.00K 10-K · filed 2016-02-29 |
| 2014-12-31 | $588.00K 10-K · filed 2015-02-27 |
| 2013-12-31 | $588.00K 10-K · filed 2014-03-03 |
| 2012-12-31 | $588.00K 10-K · filed 2013-02-28 |